Phase 2, Non-Interventional, Clinical Study to Assess Dystrophin Levels in Subjects With Nonsense Mutation Duchenne Muscular Dystrophy Who Have Been Treated With Ataluren for ≥9 Months
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacodynamics
- Sponsors PTC Therapeutics
- 06 Nov 2019 Status changed from recruiting to completed.
- 25 Jul 2019 Status changed to recruiting.
- 25 Jul 2019 Planned End Date changed from 24 May 2019 to 30 Sep 2019.